Hualan Biological Bacterin Inc
SZSE:301207
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15.63
27.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Hualan Biological Bacterin Inc
Additional Paid In Capital
Hualan Biological Bacterin Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hualan Biological Bacterin Inc
SZSE:301207
|
Additional Paid In Capital
¥2.9B
|
CAGR 3-Years
49%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Additional Paid In Capital
¥81.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Additional Paid In Capital
¥27.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Additional Paid In Capital
¥3.3B
|
CAGR 3-Years
95%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Additional Paid In Capital
¥3.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
90%
|
CAGR 10-Years
N/A
|
|
Hualan Biological Bacterin Inc
Glance View
In the bustling landscape of biotechnology, Hualan Biological Bacterin Inc. emerges as a formidable player. This Chinese company, rooted in the province of Henan, has carved its niche in the development and manufacture of human vaccines. Hualan's journey began with a focused vision on advancing public health through immunization. Today, it stands among the largest producers of human vaccines in China, adeptly navigating the stringent regulatory environments that govern this critical sector. The company's innovative approach in vaccine research is bolstered by state-of-the-art facilities and an unwavering commitment to quality, enabling it to produce safe, effective, and affordable vaccines. Over the years, Hualan has expanded its portfolio to include vaccines for influenza, rabies, and measles, to name a few, each product carefully developed to meet domestic and international health needs. Hualan Biological Bacterin Inc. generates its revenues substantially through the sale of these vaccines. The company's business model leans heavily on its strong distribution network, which ensures that its products effectively reach healthcare providers and institutions across China. Regulatory approvals for new vaccines further pave the way for market expansion and potential export opportunities, contributing to revenue growth. Furthermore, the company strategically invests in research and development, consistently working on new immunological breakthroughs, thus securing its standing and paving the way for future revenue streams. Through this meticulous combination of development, regulatory savvy, and strategic distribution, Hualan not only sustains its financial health but continues to play a vital role in advancing global public health.
See Also
What is Hualan Biological Bacterin Inc's Additional Paid In Capital?
Additional Paid In Capital
2.9B
CNY
Based on the financial report for Dec 31, 2023, Hualan Biological Bacterin Inc's Additional Paid In Capital amounts to 2.9B CNY.
What is Hualan Biological Bacterin Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
49%
Over the last year, the Additional Paid In Capital growth was -6%. The average annual Additional Paid In Capital growth rates for Hualan Biological Bacterin Inc have been 49% over the past three years .
You don't have any saved screeners yet
